Selected article for: "acute aki kidney injury and admission scr"

Author: Rubin, Sébastien; Orieux, Arthur; Prevel, Renaud; Garric, Antoine; Bats, Marie-Lise; Dabernat, Sandrine; Camou, Fabrice; Guisset, Olivier; Issa, Nahema; Mourissoux, Gaelle; Dewitte, Antoine; Joannes-Boyau, Olivier; Fleureau, Catherine; Rozé, Hadrien; Carrié, Cédric; Petit, Laurent; Clouzeau, Benjamin; Sazio, Charline; Bui, Hoang-Nam; Pillet, Odile; Rigothier, Claire; Vargas, Frederic; Combe, Christian; Gruson, Didier; Boyer, Alexandre
Title: Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019
  • Cord-id: mrznt2dx
  • Document date: 2020_6_6
  • ID: mrznt2dx
    Snippet: BACKGROUND: Coronavirus disease 2019 (COVID-19)-associated acute kidney injury (AKI) frequency, severity and characterization in critically ill patients has not been reported. METHODS: Single-centre cohort performed from 3 March 2020 to 14 April 2020 in four intensive care units in Bordeaux University Hospital, France. All patients with COVID-19 and pulmonary severity criteria were included. AKI was defined using Kidney Disease: Improving Global Outcomes (KDIGO) criteria. A systematic urinary an
    Document: BACKGROUND: Coronavirus disease 2019 (COVID-19)-associated acute kidney injury (AKI) frequency, severity and characterization in critically ill patients has not been reported. METHODS: Single-centre cohort performed from 3 March 2020 to 14 April 2020 in four intensive care units in Bordeaux University Hospital, France. All patients with COVID-19 and pulmonary severity criteria were included. AKI was defined using Kidney Disease: Improving Global Outcomes (KDIGO) criteria. A systematic urinary analysis was performed. The incidence, severity, clinical presentation, biological characterization (transient versus persistent AKI; proteinuria, haematuria and glycosuria) and short-term outcomes were evaluated. RESULTS: Seventy-one patients were included, with basal serum creatinine (SCr) of 69 ± 21 µmol/L. At admission, AKI was present in 8/71 (11%) patients. Median [interquartile range (IQR)] follow-up was 17 (12–23) days. AKI developed in a total of 57/71 (80%) patients, with 35% Stage 1, 35% Stage 2 and 30% Stage 3 AKI; 10/57 (18%) required renal replacement therapy (RRT). Transient AKI was present in only 4/55 (7%) patients and persistent AKI was observed in 51/55 (93%). Patients with persistent AKI developed a median (IQR) urine protein/creatinine of 82 (54–140) (mg/mmol) with an albuminuria/proteinuria ratio of 0.23 ± 20, indicating predominant tubulointerstitial injury. Only two (4%) patients had glycosuria. At Day 7 after onset of AKI, six (11%) patients remained dependent on RRT, nine (16%) had SCr >200 µmol/L and four (7%) had died. Day 7 and Day 14 renal recovery occurred in 28% and 52%, respectively. CONCLUSION: Severe COVID-19-associated AKI is frequent, persistent, severe and characterized by an almost exclusive tubulointerstitial injury without glycosuria.

    Search related documents:
    Co phrase search for related documents
    • acute aki kidney injury and admission cohort: 1, 2, 3, 4
    • acute aki kidney injury and admission exposure: 1, 2
    • acute aki kidney injury and admission prior: 1, 2, 3, 4, 5, 6
    • acute aki kidney injury and admission reason: 1
    • acute kidney disease and admission cohort: 1
    • acute kidney disease and admission exposure: 1
    • acute kidney disease and admission prior: 1, 2, 3, 4, 5
    • acute physiology score and admission prior: 1